Roche fronts $61m in DARPin deal with Molecular Partners
This article was originally published in Scrip
Executive Summary
Roche has agreed to pay CHF55m ($61m) in up-front and initiation payments to Molecular Partners in a deal which will see the latter's novel class of small proteins – known as DARPins – conjugated to Roche drugs to treat cancer.